Market Closed -
Nasdaq
16:00:00 2024-06-28 EDT
|
5-day change
|
1st Jan Change
|
21.53
USD
|
+0.47%
|
|
-4.23%
|
-28.16%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
1,233
|
3,322
|
1,407
|
1,481
|
2,702
|
1,955
|
-
|
-
|
Enterprise Value (EV)
1 |
1,233
|
3,066
|
1,018
|
1,125
|
2,295
|
1,762
|
1,843
|
1,714
|
P/E ratio
|
-14.4
x
|
-21.8
x
|
-8.18
x
|
-6
x
|
-10.3
x
|
-7.73
x
|
-8.68
x
|
-153
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
-
|
-
|
89.5
x
|
15.6
x
|
4.04
x
|
EV / Revenue
|
-
|
-
|
-
|
-
|
-
|
80.6
x
|
14.7
x
|
3.54
x
|
EV / EBITDA
|
-16.2
x
|
-23
x
|
-6.21
x
|
-5.94
x
|
-9.01
x
|
-8.25
x
|
-10.1
x
|
13
x
|
EV / FCF
|
-14
x
|
-32.2
x
|
-7.91
x
|
-6.03
x
|
-10.9
x
|
-7.86
x
|
-9.45
x
|
-35.5
x
|
FCF Yield
|
-7.13%
|
-3.11%
|
-12.7%
|
-16.6%
|
-9.21%
|
-12.7%
|
-10.6%
|
-2.82%
|
Price to Book
|
-
|
6.03
x
|
3.1
x
|
3.16
x
|
5.49
x
|
5.31
x
|
7.09
x
|
4.62
x
|
Nbr of stocks (in thousands)
|
54,174
|
60,570
|
64,443
|
75,684
|
90,159
|
90,782
|
-
|
-
|
Reference price
2 |
22.76
|
54.84
|
21.83
|
19.57
|
29.97
|
21.53
|
21.53
|
21.53
|
Announcement Date
|
20-03-05
|
21-02-25
|
22-02-24
|
23-02-27
|
24-02-26
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
21.85
|
125.2
|
483.5
|
EBITDA
1 |
-76.05
|
-133.2
|
-164
|
-189.4
|
-254.7
|
-213.5
|
-182.3
|
132.1
|
EBIT
1 |
-76.15
|
-134.3
|
-167.2
|
-224.3
|
-259.7
|
-286
|
-244.3
|
-14.45
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-1,308.91%
|
-195.2%
|
-2.99%
|
Earnings before Tax (EBT)
1 |
-77.27
|
-139.7
|
-169.1
|
-221.9
|
-245.6
|
-274.7
|
-252.9
|
-67.55
|
Net income
1 |
-77.27
|
-139.7
|
-169.1
|
-221.9
|
-245.6
|
-275.5
|
-248.1
|
-95.17
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-1,261.13%
|
-198.25%
|
-19.68%
|
EPS
2 |
-1.580
|
-2.520
|
-2.670
|
-3.260
|
-2.920
|
-2.786
|
-2.482
|
-0.1406
|
Free Cash Flow
1 |
-87.93
|
-95.25
|
-128.8
|
-186.5
|
-211.4
|
-224.2
|
-195
|
-48.3
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-1,026.19%
|
-155.77%
|
-9.99%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
20-03-05
|
21-02-25
|
22-02-24
|
23-02-27
|
24-02-26
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
1.949
|
21.15
|
5
|
5
|
EBITDA
1 |
-43.28
|
-
|
-53.18
|
-49.73
|
-58.34
|
-52.14
|
-57.32
|
-53.89
|
-61.88
|
-65.66
|
-65.9
|
-57.35
|
-43.85
|
-
|
-
|
EBIT
1 |
-44.33
|
-42.56
|
-54.21
|
-58.49
|
-69.08
|
-62.19
|
-68.76
|
-65.43
|
-63.28
|
-67.38
|
-69.31
|
-70.08
|
-71.08
|
-68.75
|
-67.1
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-3,595.51%
|
-336.07%
|
-1,375%
|
-1,341.95%
|
Earnings before Tax (EBT)
1 |
-44.25
|
-42.98
|
-54.4
|
-57.76
|
-66.72
|
-58.34
|
-65.7
|
-61.9
|
-59.66
|
-62.05
|
-67.22
|
-67.8
|
-69.26
|
-68.75
|
-67.1
|
Net income
1 |
-44.25
|
-42.98
|
-54.4
|
-57.76
|
-66.72
|
-58.34
|
-65.7
|
-61.9
|
-59.66
|
-62.05
|
-68.02
|
-68.83
|
-70.75
|
-68.75
|
-67.1
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-3,531.34%
|
-334.5%
|
-1,375%
|
-1,341.95%
|
EPS
2 |
-0.6900
|
-0.6700
|
-0.8300
|
-0.8700
|
-0.8900
|
-0.7300
|
-0.8200
|
-0.7500
|
-0.6400
|
-0.6600
|
-0.7238
|
-0.7292
|
-0.7466
|
-0.7333
|
-0.7233
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
22-02-24
|
22-05-05
|
22-08-08
|
22-11-03
|
23-02-27
|
23-05-04
|
23-08-09
|
23-11-07
|
24-02-26
|
24-05-06
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
256
|
389
|
356
|
407
|
193
|
111
|
240
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-87.9
|
-95.2
|
-129
|
-187
|
-211
|
-224
|
-195
|
-48.3
|
ROE (net income / shareholders' equity)
|
-
|
-34.5%
|
-35.3%
|
-47%
|
-50%
|
-59.7%
|
-57.9%
|
33.4%
|
ROA (Net income/ Total Assets)
|
-
|
-29%
|
-31.1%
|
-42.3%
|
-43.9%
|
-54.7%
|
-57.8%
|
-27.4%
|
Assets
1 |
-
|
481.5
|
543.9
|
524.4
|
559.1
|
503.7
|
429.3
|
347.3
|
Book Value Per Share
2 |
-
|
9.090
|
7.050
|
6.190
|
5.460
|
4.050
|
3.040
|
4.660
|
Cash Flow per Share
2 |
-
|
-
|
-1.920
|
-2.610
|
-2.320
|
-2.600
|
-2.130
|
-
|
Capex
1 |
23.3
|
20.6
|
7.62
|
8.36
|
16.4
|
11
|
11.2
|
10.8
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
50.16%
|
8.94%
|
2.24%
|
Announcement Date
|
20-03-05
|
21-02-25
|
22-02-24
|
23-02-27
|
24-02-26
|
-
|
-
|
-
|
Last Close Price
21.53
USD Average target price
49.62
USD Spread / Average Target +130.45% Consensus |
1st Jan change
|
Capi.
|
---|
| -28.16% | 1.95B | | +15.20% | 121B | | +19.67% | 113B | | +18.95% | 26.02B | | -23.86% | 19.39B | | -19.03% | 15.91B | | -20.90% | 15.09B | | -46.14% | 15.06B | | +63.85% | 14.93B | | +4.49% | 13.85B |
Bio Therapeutic Drugs
|